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Abstract
Motivation: Epigenetic heterogeneity within a tumour can play an important role in tu-
mour evolution and the emergence of resistance to treatment. It is increasingly recognised that
the study of DNA methylation (DNAm) patterns along the genome – so-called ‘epialleles’ – of-
fers greater insight into epigenetic dynamics than conventional analyses which examine DNAm
marks individually.
Results: We have developed a Bayesian model to infer which epialleles are present in multiple
regions of the same tumour. We apply our method to reduced representation bisulfite sequenc-
ing (RRBS) data from multiple regions of one lung cancer tumour and a matched normal
sample. The model borrows information from all tumour regions to leverage greater statistical
power. The total number of epialleles, the epiallele DNAm patterns, and a noise hyperparame-
ter are all automatically inferred from the data. Uncertainty as to which epiallele an observed
sequencing read originated from is explicitly incorporated by marginalising over the appropri-
ate posterior densities. The degree to which tumour samples are contaminated with normal
tissue can be estimated and corrected for. By tracing the distribution of epialleles throughout
the tumour we can infer the phylogenetic history of the tumour, identify epialleles that differ
between normal and cancer tissue, and define a measure of global epigenetic disorder.
Availability: R code is available at github.com/james-e-barrett.
Contact: regmjeb@ucl.ac.uk
1 Introduction
Epigenetic variability allows greater phenotypic diversity and plasticity within a population of genet-
ically similar cells. Epigenetic diversity within a tumour provides a mechanism for clonal evolution
and the emergence of resistance to therapy (Mazor et al., 2016). Persistence of treatment-resistant
∗Contact: regmjeb@ucl.ac.uk
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subclonal populations may explain the failure of some therapies, and higher levels of heterogeneity
have been associated with poorer clinical outcomes (Landau et al., 2014). Analysing multiple tissue
samples from different tumour regions facilitates quantification of tumour heterogeneity and phylo-
genetic analyses. Pan et al. (2015) showed that intra-tumour DNAm heterogeneity is predictive of
time-to-relapse in diffuse B-cell lymphomas. Brocks et al. (2014) have shown that both epigenetic
and genetic alterations reflect the evolutioary history of prostate cancers. A recent study of Ewing
sarcoma found substantial levels of epigenetic heterogeneity within tumours (Sheffield et al., 2017).
Epigenetic modifications play an important role in the regulation of gene expression. One of the
most common types is DNA methylation (DNAm) — where a methyl group is added to cytosine.
We will focus on DNAm in the canonical CpG context where cytosine (C) is followed by guanine
(G). High levels of DNAm in promoter regions are associated with suppressed gene expression
whereas increased methylation in gene body regions tends to have the opposite effect (Suzuki and
Bird, 2008).
Reduced representation bisulfite sequencing (RRBS) is a sequencing technique that measures
DNAm (Gu et al., 2011). The experimental protocol consists of treating DNA with bisulphite
which converts unmethylated cytosines into uracils. During the amplification process uracils are
converted into thymines. After sequencing and comparison to a reference genome, unconverted
CpGs are identified as unmethylated and vice versa. The RRBS technique does not sequence the
entire genome, but rather regions of the genome that are enriched for CpGs. This naturally splits
the genome into distinct loci which can be analysed separately.
Conventional analyses of DNAm have focused on the average DNAm level per CpG site. This is
obtained by examining all of the sequencing reads which contain a given CpG and simply counting
how many times it is methylated. This type of analysis, however, fails to take into account the
full methylation pattern at a given locus which can be observed by looking at all contiguous CpGs
along a sequencing read. If there are d CpG sites on one read then there are 2d possible methylation
patterns, which are called epialleles (Richards, 2006). Sequencing reads that cover the same d CpG
sites can be compared, and the frequency of distinct epialleles that are present can be calculated.
Since each DNA fragment comes from a different cell (more precisely a different allele) this provides a
snapshot of how many distinct cellular subpopulations are present within the sample. The additional
information acquired from contiguous CpG sites on sequencing reads is not present using array-
based platforms. It is becoming clear that leveraging this extra information offers potential insights
into the epigenetic landscape that would otherwise be missed (Li et al., 2014; Lin et al., 2015; He
et al., 2013).
If multiple samples are taken from the same tumour then each sample can be analysed to see
which epialleles are present, and in what proportion, at a given loci. By tracing the presence and
absence of different epialleles across different regions of the tumour and matched normal tissue it is
possible to reconstruct the evolutionary history of the tumour regions, and to probe for significant
differences between normal and tumour tissue. Moreover, the diversity of epialleles within the
tumour provides a measure of overall epigenetic heterogeneity.
The acquisition of tumour samples may result in a mixture of both tumour and normal tissue.
By comparing the expression of epialleles within the tumour samples and matched normal tissue it
is possible to estimate the sample purity — the proportion of the sample which is tumour tissue.
Furthermore, it is possible to decontaminate the tumour samples by effectively ‘subtracting’ that
component of the epiallele profile which can be attributed to the contaminating normal tissue. An
analysis of differential epiallele expression and phylogenetics can be conducted after decontamina-
tion.
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We present a Bayesian statistical model to infer which epialleles are present at a given locus.
The model infers the epialleles that are present and which epiallele each observed sequencing read
corresponds to. One hyperparameter controls the level of noise in the model (which represents
errors due to bisulfite conversion, PCR amplification, and sequencing) and this is also inferred from
the data. Finally, the total number of distinct epialleles is inferred. This final step is a model
selection problem and we use the Akaike Information Criterion to avoid overfitting the model. The
Bayesian approach allows the quantification of uncertainty regarding the model parameters. In
particular, there may be some ambiguity as to which epiallele a certain observed read corresponds
to (if some epialleles are very similar to each other for instance). This uncertainty is incorporated
into the epiallele distribution by averaging over the appropriate model parameters with respect to
the corresponding posterior density.
1.1 Related work
The additional information garnered from adjacent CpGs can be used to define a measure of vari-
ability or heterogeneity within a biological sample. The concept of ‘epipolymorphism’, for instance,
has been proposed by Landan et al. (2012). Xie et al. (2011) define a measure of ‘methylation en-
tropy’ based on the Shannon entropy and Landau et al. (2014) developed the concept of ‘proportion
of discordant reads’.
The term allele-specific methylation has also been used to refer to epialleles. Statistical models
have been developed by Peng and Ecker (2012); Fang et al. (2012); Wu et al. (2015) to identify
epialleles at a given locus and which epiallele each observed read originated from. These models can
infer multiple epialleles but in applications only two epialleles have been assumed. An algorithm
to estimate tumour purity and deconvolve the epigenomes of tumour and normal tissue uses a very
similar statistical model (Zheng et al., 2014).
Li et al. (2014) compare the epiallele distribution at two disease stages using a ‘composition
entropy difference calculation’. They identify loci with substantial shifts in epiallele composition.
They confine their analysis to epialleles defined by four CpG sites. Lee et al. (2015) used multinomial
logistic regression to test for differences in the epiallele distribution between normal and cancer cells.
They report performance that is very similar to the method of Li et al. (2014), but do not constrain
their approach to four CpGs. In both of these approaches the epialleles are identified from the raw
sequencing data, without any inference step to account for experimental noise.
Lin et al. (2015) develop a statistical model that explicitly takes into account measurement
noise due to bisulfite conversion and sequencing errors. The model allows identification of ‘spurious’
epialleles that are due to measurement error (spurious epialleles will tend to have low counts and be
very similar to a dominant epiallele). Noise parameters are manually estimated from experimental
data, and missing data are not facilitated by their model.
In summary, an adequate epiallele analysis of DNAm sequencing data should have the following
features. It should answer the basic research question of whether there is a difference in the epiallele
composition between two or more groups of samples — and identify the loci at which there are
significant differences. Ideally, some measures need to be taken to avoid spurious epiallele detection
due to experimental noise. In addition, an analysis method will generally need to accommodate
variable sequencing depth per loci, a variable number of contiguous CpGs per sequencing read, and
missing data. Missing data can arise from partially overlapping reads or gaps in a read due to
non-overlapping paired-end sequencing protocols.
In addition to the above features, our Bayesian approach automatically infers all model pa-
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Figure 1: (a) An example of a genomic locus (chr1:1,145,478-1,145,614) in which each row
corresponds to a sequencing read. Black and white circles represent methylated and un-
methylated CpGs respectively. Note that some CpG measurements are missing. (b) The
four epialleles that are inferred from the observed sequencing reads. (c) The Akaike Informa-
tion Criterion score versus the total number of epialleles. The inferred number of epialleles
corresponds to the minimum AIC score. (d) The proportion of observed reads attributed to
each epiallele after marginalisation over the parameter w (see main text for details).
rameters (including the total number of epialleles) from the observed data. Ambiguity in model
parameters is explicitly incorporated in our analysis by averaging over the appropriate Bayesian
posterior density (descried in detail below). We have applied our method to data from multiple tu-
mour regions and matched normal tissue. We have developed a protocol for estimating the tumour
sample purity and consequently decontaminating the inferred epiallele profiles. Although we have
focused on multi-region tumour sampling our method could be applied to a single sample also.
2 Methods
Sequencing reads are aligned to the reference genome and organised into different genomic loci. A
locus is a region of the genome containing d CpG sites (d can take different values to each locus).
Due to the nature of RRBS data the sequencing reads naturally tend to form non-overlapping loci.
Some additional steps were taken to modify loci in order to control the amount of missing data per
locus. See Supplementary Material A for full details.
Let N denote the number of sequencing reads at a given locus. To keep our notation compact
we will avoid indexing each locus and what follows here is applicable to any locus of the genome. A
sequencing read is represented by a d-dimensional vector yi ∈ {0, 1}d where i = 1, . . . , N and 0 and
1 correspond to unmethylated and methylated CpG sites respectively. An example is plotted in
Figure 1 (a). It is assumed that each observed read can be attributed to one of Q epialleles xq with
q = 1, . . . , Q and Q ≤ N . The parameter wi ∈ (1, . . . , Q) specifies which epiallele read yi originated
from. The observed methylation status of each CpG may differ from the corresponding epiallele
status with probability  ∈ [0, 1/2]. Supposing wi = q we can therefore write p(yi|xq, , Q) =∏d
µ=1 p(yiµ|xqµ, , Q) where
p(yiµ|xqµ, , Q) =
{
 if yiµ 6= xqµ
1−  if yiµ = xqµ. (1)
The epialleles are analogous to latent variables in a latent variable model. Our goal is to infer the
quantities X = (x1, . . . ,xQ) and w = (w1, . . . , wN ) as well as the hyperparameter  and the number
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of epialleles Q from the observed data Y = (y1, . . . ,yN ). Using Bayes’ theorem the posterior over
the unknown quantities is
p(X,w, |Y, Q) = p(Y|X,w, , Q)p(X|Q)p(w|Q)
p(Y|Q) (2)
where the likelihood is
p(Y|X,w, , Q) =
N∏
i=1
Q∑
q=1
δq,wi p(yi|xq, , Q). (3)
The delta function is defined by δxy = 1 if x = y and δxy = 0 otherwise. The marginal density
p(Y|Q) = ∑X′ ∑w′ ∫ d′ p(Y|X,w, , Q)p(X|Q)p(w|Q) serves to normalise the posterior density
where the summation is over all possible values of X and w. We will use maximum entropy priors
which are uniform densities over the 2Qd possible epiallele configurations X and QN possible values
of w.
2.1 Bayesian inference
For fixed X, , and Q, the maximum a posteriori (MAP) estimate for w is given by attributing
each read yi to the epiallele that is most similar to it. That is,
w∗i = argmaxqp(yi|xq, , Q). (4)
Next we wish to obtain the MAP estimate for xqµ for fixed w,  and Q. Let N1 denote the total
number of methylated CpGs at site µ in observed reads that have been attributed to epiallele q.
That is, N1 =
∑
i yiµ where the sum is restricted to indices for which wi = q. Similarly, N0
is the total number of unmethylated CpGs at site µ in reads stemming from epiallele q. It is
straightforward to show that the MAP estimate is
x∗qµ = 1 if N1 > N0
x∗qµ = 0 otherwise. (5)
We now define the total matches at a given locus as α1 =
∑
i,µ δyiµ,xwiµ and mismatches as α0 =∑
i,µ 1− δyiµ,xwiµ . It can be shown (see Supplementary Material) that the MAP estimate for  is
∗ =
α0
α0 + α1
(6)
which is simply the proportion of observed CpGs at that locus that differ from the underlying
epialleles. Some values of yiµ may be missing and these are handled by simply omitting them from
sums and products over i and µ.
2.1.1 Algorithm
Note that the MAP estimates w∗ and X∗ are independent of . Given a set of observed data Y
the first task is to determine optimal values for w and X. This is done according to the following
algorithm:
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1. Initialise w by using hierarchical clustering to group the observed reads Y into Q groups.
The hamming distance (the proportion of CpGs that differ between two sequencing reads) is
used as a distance measure.
2. Compute X according to (5) using the current estimate of w.
3. Compute w according to (4) using the current estimate of X.
4. Repeat steps 2 and 3 until w and X converge to a steady solution (typically two or three
iterations).
Denote the final parameter values as wˆ and Xˆ. The value for ˆ is then given by (6).
2.1.2 Model selection
In principle, the marginal density p(Y|Q) could be used to compare models with different values of
Q. In practice, however, p(Y|Q) is analytically intractable. Instead we use the Akaike information
criterion (AIC) (Akaike, 1998) in order to select the optimal number of epialleles
AIC(Q) = −2 log p(Y|Xˆ, wˆ, ˆ, Q) + 2Qd (7)
where Qˆ = argminQAIC(Q). For a model with Q epialleles the Qd parameters that make up the
matrix X are regarded as free parameters. The term 2Qd penalises more complex models (i.e.
models with larger Q). A more complex model will only be selected if the evidence from the data
is sufficiently strong to overcome the penalty term.
2.1.3 Marginalisation of w
Finally, it may not be completely clear which epiallele an observed read should be attributed to
(there could be several epialleles an equal edit distance away). This ambiguity manifests itself as
the uncertainty surrounding the parameter wi. The Bayesian approach allows this uncertainty to be
incorporated into our analysis. The marginal density over wi is given by fixing all other parameters
to their MAP values
p(wi|wˆ−i, Xˆ, ˆ, Qˆ) = p(Y|Xˆ, wˆ−i, wi, ˆ, Qˆ)p(Xˆ|Qˆ)p(wˆ|Qˆ)
p(Y|Qˆ) (8)
where wˆ−i is a (d − 1)-dimensional vector obtained from wˆ by removing element i. At the given
locus in question the proportion of observed reads originating from epiallele q is given by
φq =
1
N
N∑
i=1
p(wi = q|wˆ−i, Xˆ, ˆ, Qˆ). (9)
The quantity φ = (φ1, . . . , φQˆ) specifies the distribution of epialleles within that locus. An example
is given in Figure 1 (d).
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2.2 Application to multi-region tumour sampling
We will now describe our analysis protocol. In our application we are considering sequencing data
from multiple regions of the same tumour. The number of distinct epialleles present at a particular
locus is determined by pooling sequencing reads from all tissue samples (tumour and normal) in
order to boost statistical power. Suppose there are s = 1, . . . , S tumour samples with Ns reads
per sample (at a given locus). The total number of reads in the pool is now N =
∑
sNs. Using
the pooled reads a model is fitted as described above. The vector wˆ defines which epiallele each
sequencing read originated from. The distribution of epialleles within region s is given by
φsq =
1
Ns
∑
i∈Is
p(wi = q|wˆ−i, Xˆ, ˆ, Qˆ) (10)
where Is is the set of indices of reads belonging to sample s. The vectors φs serve to characterise
each sample in terms of their epiallele distributions.
2.2.1 Estimation of sample purity
Suppose Qˆ epialleles are inferred at particular locus of a particular tumour sample (for the sake of
compactness we will not index the loci or samples). The locus is characterised by φ, the inferred
probability distribution over the Qˆ epialleles. If the tumour sample is contaminated with normal
tissue then we can write
φ = ρt+ (1− ρ)n (11)
where ρ ∈ [0, 1] is the proportion of observed tissue that comes from the tumour (the sample
‘purity’), and t and n are the epiallele distributions in the tumour and normal tissues respectively
(at the particular locus in question). We can estimate φ and n from the observed data at a particular
locus. Estimation of both ρ and t requires solving the Qˆ equations in (11) for Qˆ+1 variables which
generally is not possible. However, the quantity
ξ =
1
2
Qˆ∑
µ=1
abs(φµ − nµ) (12)
can be computed at each locus of the observed tissue sample. If we substitute (11) into (12) we can
see that ξ takes a minimum value of 0 when t = n. At a locus in which the tumour and normal
tissues have a completely different epiallele composition then we say that if tµ > 0 then nµ = 0 and
if nµ > 0 then tµ = 0 for µ = 1, . . . , Qˆ. It is straightforward to show that if this is the case then
ξ = ρ and that this is the maximum value ξ can take.
We therefore expect that ξ will take values in the range [0, ρ] when computed across all loci of
the observed sample. If we plot the empirical density of ξ values the parameter ρ can be estimated
from the maximum value of ξ. Since φ and n are estimated from finite data samples we expect the
distribution of ξ to be ‘smoothed’ by sampling noise. This is precisely what we observe in practice.
An example of the empirical density of ξ is plotted in Figure 11.
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2.2.2 Decontamination of normal tissue
Finally, we note that once estimates of ρ have been obtained we can calculate the ‘decontaminated’
tumour epiallele profiles at each locus according to
tˆµ =
φµ − (1− ρ)nµ
ρ
for µ = 1, . . . , Qˆ. (13)
We have used the notation tˆµ to emphasise that this is an estimate of the tumuor epiallele distri-
bution. Due to the fact that φ, n and ρ are estimated from finite data samples it is possible that
tˆµ can take values outside [0, 1]. Any cases where tˆµ < 0 are set to 0 and any cases where tˆµ > 1
are set to 1.
A conventional anlaysis of DNAm sequencing data will typically ‘call’ a methylation level at
each CpG site by computing the proportion of reads on which a CpG is observed in a methylated
state. Using our method a methylation level for each CpG site can readily be computed after
decontamination of normal tissue and used in existing analysis pipelines.
2.2.3 Construction of a phylogenetic tree
Using the decontaminated representation of a sample tˆs the euclidean distance between tˆs and tˆs′
can be used as a distance measure between samples s and s′. Each locus provides a distance matrix
that depends on the distribution of epialleles at that particular locus. To obtain an overall distance
matrix we average over distance matrices from all loci. Any distance based phylogenetic inference
method can subsequently be used to construct a phylogenetic tree. We used the ‘fastme.bal’ function
as part of the ‘ape’ R package (Paradis et al., 2004).
3 Results
3.1 Simulations
Simulations of a single locus were performed to study what effect the number of CpGs, d, the
number of sequencing reads, N , and the noise level, , have on our ability to correctly detect the
underlying epialleles. The simulated reads were noise corrupted versions of three distinct randomly
generated epialleles, and on average each epiallele corresponded to one third of the observed reads.
To assess model performance we counted the proportion of observed reads that were attributed
to their correct underlying epiallele (which requires both inference of the correct epialleles and
attribution to the correct epiallele). For every value of the parameters results were averaged over
100 simulations.
We found that N = 100 and d = 6 gave a success rate of approximately 95% at a 5% noise level.
These values were used to guide the selection of viable loci in subsequent analyses of experimental
data. Dropping to N = 50 gave a performance of just over 90% (Supplementary Figure 3). Se-
quencing depth beyond N = 100 did not yield any additional performance gain. The performance
saturates at 100% for d > 15 (Supplementary Figure 4). Since the number of possible epialleles is
2d a larger d will typically make it easier to resolve distinct epialleles. Additionally, since the un-
derlying epialleles are randomly generated it is possible that some may be within one edit distance
from each other, making it difficult for the model to distinguish between very similar epialleles and
noise when d is small. Performance was observed to decrease sharply for increasing noise levels
(Supplementary Figure 5).
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Figure 2: A genomic locus (chr1:2,603,277-2,603,489) composed of seven CpGs. The distri-
bution of five epialleles – inferred using the Bayesian model – are plotted for seven tumour
regions (R1 to R7) and one normal sample (N). In (a) the tumour samples have not been cor-
rected for normal tissue contamination whereas in (b) they have been. The tumour samples
are shifting towards an unmethylated profile in comparison to the normal tissue.
3.2 Cell line data: detection of low frequency epialleles
In order to test whether our statistical methods could detect low frequency epialleles in practice we
mixed a fully unmethylated and fully methylated cell line in a 9:1 ratio prior to sequencing. Loci
with six or more CpGs and 50 or more reads were identified. Within these loci 6.3% of observed
CpGs were methylated overall. The two cell lines were sequenced separately and we found that the
fully methylated and unmethylated cells were in fact 97.3% and 3.8% methylated respectively.
The Bayesian model was used to detect the presence of epialleles at each loci. We found that
5.2% of methylated CpGs were attributed to methylated epialleles (defined as epialleles with ≥ 50%
methylation). The mean noise level was inferred as 1.1%. This suggests that the majority of
methylation is correctly identified as corresponding to a methylated profile and therefore our method
is capable of resolving a distinct low frequency cellular subpopulation.
3.3 Multi-region tumour sampling case study
Our case study data consisted of seven tissue samples from a single lung tumour (CRUK00620)
along with one matched normal tissue sample. These tissue samples were acquired as part of the
larger TRACERx study (Jamal-Hanjani et al., 2017). The raw sequencing data were trimmed and
aligned to a reference genome. Sequencing reads were subsequently organised into distinct genomic
loci as described in the Supplementary Material. We demanded that no more than 25% of data
were missing per locus (due to partially overlapping paired-end reads or reads not covering the
whole locus). Any data from chromosomes X and Y were discarded. At each locus Qˆ epialleles are
inferred and any epialleles that accounted for less than 5% of observed reads were discarded prior
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Figure 3: Estimation of tumour sample purity for region 2 of the tumour. The parameter ξ
was calculated at all eligible loci across the genome and the empirical distribution is plotted
here. The sample purity is equal to the maximum value of ξ which is interpreted to occur
at the rightmost maximum at ξ = 0.53. The distribution of ξ is ‘smoothed’ due to the fact
that at each locus ξ is estimated from a finite sample of sequencing reads.
to the computation of φs for s = 1, . . . , S. This was done in order to focus on the dominant shifts
in epiallele profiles and to minimise the risk of inferring spurious epialleles.
In order to compare the distribution of epialleles within different tumour samples it was necessary
to identify all of the loci which occurred in two or more samples. That is, the loci themselves must
‘match up’ between tumour samples in order for a comparison to be made (partially overlapping
loci were permitted provided they met the minimum number of non-missing CpG requirements).
Only loci with a median read depth ≥ 100 across normal and tumour tissue samples and six or
more CpGs were considered. A total of 39,940 loci were analysed out of which 73% were found to
contain a single epiallele, 13% contained two, 7% contained three, 4% contained four, and 3% had
five our more (up to a maximum of thirteen).
3.3.1 Comparison of epiallele distribution throughout the tumour
At each locus the Bayesian model is used to infer the epialleles present, the total number of epialleles,
and which epialleles each observed sequence came from. An example locus with seven CpGs from
chromosome one is presented in Figure 2. At this locus five distinct epialleles were detected.
Both the observed and decontaminated profiles are shown. The normal tissue is predominantly
composed of methylated epialleles whereas the tumour samples have a greater proportion of less
methylated epialleles. This suggests that within the tumour there exist cellular subpopulations that
are undergoing a transition from a methylated state to an unmethylated one.
In order to understand shifts in epiallele frequency at a global level we plotted a heatmap of the
top 200 most variable epialleles in Figure 4 (a) and (c). Both the observed and decontaminated
epiallele profiles were used. Tumour samples are characterised by both a loss and gain of numer-
ous epialleles when compared to the normal tissue sample. The variability in epiallele expression
throughout different parts of the tumours suggests that a substantial level of tumour heterogeneity
exists at the epigenetic level. Note that in the contaminated samples 71 out of the 200 epialleles
were located on CpG islands, and 54 were located on a CpG shore (defined as 2 kilobases either
side of an island). In the decontaminated version 124 epialleles were located on an island and 38
on a shore.
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Figure 4: (a) Heatmap of the top 200 most variable epialleles across the seven tumour
samples (labelled R1 to R7) and matched normal sample (labelled N). A proportion of 1.0
(dark blue) means that that epiallele accounted for all observed methylation patterns at the
corresponding locus. These data have not been decontaminated of normal tissue. (b) The
phylogenetic tree inferred before correction for contaminating normal tissue. In (c) and (d)
are the same figures for the decontaminated epiallele profiles.
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Figure 5: Box plots of the Shannon entropy of the epiallele distribution across normal tissue
(N) and the seven tumour regions (R1–R7).
3.3.2 Estimation of sample purity
The sample purities were estimated as described in Section 2.2.1. An example of the empirical
density of ξ within tumour region 2 is plotted in Figure 11. From the location of the rightmost
maximum we estimate ρ = 0.535. Plots for all tumour regions are given in Supplementary Figure
6. Estimates of purity for the seven tumour samples are given in Table 1. For tumour region 6 the
rightmost maxima was not visible presumably due to very low tumour purity. The purity estimates
are compared to estimates obtained from an analysis of exome data from the same tissue samples
performed independently in Jamal-Hanjani et al. (2017).
3.3.3 Inference of a phylogenetic tree
Phylogenetic trees were generated as described in Section 2.2.3. The trees for both contaminated
and decontaminated samples are plotted in Figure 4 (b) and (d). The structure of the contaminated
tree is dominated by the sample purities, with low purity samples clustering together. The decon-
taminated tree has a totally different structure and this is broadly similar to a phylogenetic tree
obtained from from a separate genetic analysis of the same patient and shown in Supplementary
Figure 7.
Tumour sample Epiallele purity estimate Exome purity estimate
R1 35% 32%
R2 54% 51%
R3 75% 73%
R4 53% 67%
R5 25% 28%
R6 <20% 13%
R7 30% 36%
Table 1: In the middle column are estimates of tumour purity based on a comparison of
epiallele distributions between normal tissue and tumour tissue. The third column contains
estimates obtained from a separate study of exome data from the same tumour samples.
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3.3.4 Quantification of epigenetic disorder
The Shannon entropy provides a measure of how disordered a random variable is. In particular,
the entropy of the epiallele distribution φs quantifies how disordered or heterogeneous each loci
is in sample s. In Figure 5 box plots summarise the distribution of entropies across tumour and
normal tissues (without decontamination). The tumour tissue samples have a substantially elevated
entropy in comparison to the normal tissue.
4 Discussion
Analysis of epialleles allows for a deeper interrogation of the underlying biology than a pointwise
examination of CpG methylation states. Tracing the patterns of DNA methylation along epialleles
allows one to tease apart different cellular subpopulations and acquire a richer quantification of
heterogeneity and disorder that would not be possible by looking at individual CpG sites. In
particular, the distribution of epialleles throughout a tumour can shed light on the evolutionary
history of the tumour.
Our analysis protocol specifically pools sequencing reads from multiple tissue samples in order to
leverage greater statistical power in epiallele detection. Our Bayesian approach will automatically
detect the number of epialleles present, and infer what the methylation pattern of those epialleles
are. One strength of the Bayesian approach is that it provides a framework for averaging over
uncertainty in model parameters. If there is uncertainty as to which epiallele an observed sequencing
read may have originated from, then a natural solution is to average over that uncertainty by
marginalising over the appropriate posterior distribution. In addition to the above features our
model can easily accommodate missing data and can handle an arbitrary sequencing depth and
number of CpG sites per locus. Furthermore, by comparing the distribution of epialleles within
normal and tumour tissue samples it is possible to estimate the purity of each sample and to
subsequently decontaminate them. Methylation levels at each CpG site can be extracted from the
decontaminated samples and subsequently used in standard analysis pipelines.
Tracking the presence or absence of epialleles throughout the tumour opens up an additional
layer of complexity beyond that of conventional methylation analyses. Pointwise methylation anal-
ysis protocols typically average over sequencing reads – to ‘call’ the methylation status at single
CpGs – that potentially come from a diverse and heterogenous population of cells. Detecting which
epialleles are present allows one to distinguish between these cellular subpopulations and identify
tumour subclones that are defined by distinct epialleles. One can then probe changes between
normal and cancerous tissue at a finer resolution. As we have demonstrated here, studying epiallele
frequencies in different parts of the tumour reveals the evolutionary history of the tumour and
allows a phylogenetic tree to be constructed. A measure of disorder or heterogeneity inside the
tumour can be obtained through measures such as Shannon’s entropy.
5 Conclusion
Understanding tumour heterogeneity is an important step towards understanding why certain ther-
apies fail and why resistance to treatment can emerge. Subclonal populations of treatment-resistant
cells can persist after treatment even if they only account for a small fraction of the original tumour.
Epigenetic diversity within the tumour may play an important role in tumour evolution alongside
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genetic variability. It is increasingly recognised that for DNA methylation sequencing data studying
the patterns of methylation along the genome – ‘epialleles’ – can provide greater insight into the
underlying dynamics of epigenetic regulation than a conventional pointwise analysis.
We have exploited this opportunity to study the distribution of epialleles throughout a tumour
by performing reduced representation bisulfite sequencing on seven regions of the same tumour
and one matched normal tissue sample. Our new Bayesian approach infers which epialleles are
present at a given locus. A comparison of the frequency of different epialleles across the tumour
and normal tissue highlights changes between normal and cancerous tissue and allows the extraction
of a phylogenetic history. The concept of entropy can be used as a measure of global disorder within
the tumour. Our method can be applied more generally to any type of DNAm sequencing data.
Future work will focus on larger scale studies of multiple patients with multi-region tumour
sampling in order to probe for systematic alterations in epiallele expression between normal and
cancerous tissue. Previously, measures of epigenetic disorder were found to be associated with
clinical outcome and it will be interesting to see if quantification of disorder at the level of epialleles
will provide a more refined measure of tumour aggressiveness. Ultimately, it is hoped that a clearer
elucidation of epigenetic dynamics will complement our genetic knowledge of cancer and provide a
more comprehensive understanding of the disease.
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A Extraction of viable loci
Figure 6: An example of an observed locus (chr1:15,232,224-15,232,587) before preprocessing.
In Figure 6 is an example of an observed locus before any preprocessing steps have been taken.
The locus is defined naturally since it does not overlap with any other observed sequencing reads.
Note that several sequencing reads only partially overlap and many do not overlap at all. In
addition, several CpG measurements are missing from the middle of some reads due to the paired-
end sequencing protocol that was used to generate the data (sometimes the paired ends may not
span the full length of the DNA fragment).
Intuitively this locus should be split into two loci as the two blocks of reads overlap by a single
CpG which is not enough to phase the inferred epialleles. We implemented the following algorithm
to split the observed sequencing reads into sensible loci.
1. Specify the minimum number of contiguous CpGs dmin and the minimum number of reads
Nmin required in order for a locus to be admissible (we used dmin = 6 and Nmin = 100 in
practice).
2. Specify the maximum proportion of missing data that is allowed (we used 25% in practice).
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3. If the observed locus contains more than 25% missing data move to the next step, otherwise
skip to step 4.
3(a). Represent the observed reads as a matrix with all non-missing measurements equal to 1
and all missing values represented with 0. Use hierarchical clustering to split the reads
into two groups using the hamming distance.
3(b). If the two groups contain less than 25% of the missing data then proceed to the next
step. Otherwise repeat the clustering above with three groups and so forth.
4. Discard any loci that fail to meet the minimum values of d and N .
We demanded that, in addition to the loci as a whole, each CpG site should not contain more
than 25% missing data. Any CpGs that failed to meet this constraint were discarded. This helped
to trim low-coverage CpGs from at the edges of observed loci (for example, the very leftmost CpG
in Figure 12). The resulting loci after preprocessing are shown in Figure 7.
Figure 7: The two loci that are extracted from the observed data in Figure 12.
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B MAP estimate for 
Given X, w, Q and uniform priors p(X|Q) and p(w|Q) the MAP estimate for the hyperparameter
 is given by maximising the log of the posterior (2):
L() = log p(Y|X,w, , Q)
= log
N∏
i=1
d∏
µ=1
p(yiµ|xwiµ, , Q)
= α0 log + α1 log(1− ). (14)
Note that on the second line that if read yi originates from epiallele q then wi = q. Recall that
α1 =
∑
i,µ δyiµ,xwiµ and α0 =
∑
i,µ 1−δyiµ,xwiµ denote the total number of matches and mismatches
between the observed reads y and the corresponding epialleles x at this particular loci. Solving
dL/d = 0 yields  = α0/(α0 + α1).
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C Simulation results
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Figure 8: Proportion of observed reads attributed to the correct underlying epiallele as a
function of N (the number of sequencing reads at the simulated locus). Parameters were
fixed to  = 0.05, d = 6 and Q = 3.
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Figure 9: Proportion of observed reads attributed to the correct underlying epiallele as
a function of d (the number of CpGs at the simulated locus). Parameters were fixed to
N = 100,  = 0.05 and Q = 3.
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Figure 10: Proportion of observed reads attributed to the correct underlying epiallele as a
function of  (the noise level). Parameters were fixed to N = 100, d = 6 and Q = 3.
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D Purity estimation
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Figure 11: Empirical density plots of ξ, the proportion of epialleles at a locus that are
different from normal tissue. The distribution of ξ will depend on the tumour purity since
samples that are contaminated with less normal tissue will exhibit a greater deviance from
the matched normal tissue epialleles. On this basis, the rightmost maxima (marked with a
dashed vertical line) of the empirical densities are interpreted as a proxy for sample purity.
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E Supplementary figures
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Figure 12: Phylogenetic tree generated from exome sequencing data from the same tumour
that is studied in the main text. The exome data were generated and analysed independently
as part of the Jamal-Hanjani et al., 2017 study. GL denotes germline.
F Experimental datasets
The RRBS data are available at the European Nucleotide Archive under accession numbers ERS1546024,
ERS1546025 and ERS1546026.
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